Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

AbbVie Inc. ABBV reported adjusted earnings of $3.00 per share for the third quarter of 2024, beating the Zacks Consensus ...

AbbVie (ABBV) stock hits all-time high after beating Q3 earnings expectations with newer immunology drugs outperforming ...

EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

AbbVie (ABBV) to acquire Aliada Therapeutics for $1.4B in cash, enhancing focus on Alzheimer's disease with innovative ...

AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current ...

Evolveimmune Therapeutics Inc. has secured its fourth big pharma investor and its first pharma development partnership in a deal with Abbvie Inc. The multitarget development deal with Abbvie includes ...

Steve Grzanich has the business news of the day with the Wintrust Business Minute. A $75 million donation from the AbbVie Foundation will help University of Chicago Medicine build its new cancer ...